FIGURE
Fig. 3
- ID
- ZDB-FIG-240202-3
- Publication
- Larsson et al., 2024 - Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer
- Other Figures
- All Figure Page
- Back to All Figure Page
Fig. 3
Prediction of potent 2-drug combinations by IDACombo. Data from the monotherapy experiments were evaluated by IDACombo, whereby we chose 11 combinations (bortezomib + doxorubicin, bortezomib + epirubicin, bortezomib + nedaplatin, delanzomib + doxorubicin, delanzomib + epirubicin, delanzomib + nedaplatin, epoxomicin + doxorubicin, epoxomicin + epirubicin, epoxomicin + nedaplatin, doxorubicin + docetaxel, and doxorubicin + nedaplatin) with combo scores >0.06 and two combinations (carboplatin + docetaxel and carboplatin + paclitaxel) currently used in clinical practice. |
Expression Data
Expression Detail
Antibody Labeling
Phenotype Data
Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ Cell Death Discov